journal article·2025-12Open access

Trained Immunity Exacerbates Inflammatory Arthritis Progression via Promoting Synovial Fibroblast Ferroptotic Resistance

Haibo Su, Baoying Zhang, Qiudi Deng, Jiaxin Huang, Jinyu Feng, Yuan Fu, Yuejun Huang, Weikun Deng, YingJun Su, Huisheng Liu, Ning‐yi Shao, Zhenhui Zhang, Jianwei Dai

Advanced Science· Volume 12· Issue 46

Abstract

Abstract Trained immunity induced by β‐glucan insult drives the functional reprogramming of macrophages to the hyperinflammatory status, contributing to developing or maintaining inflammatory diseases. Inflammatory arthritis is characterized by an idiopathically hyperinflammatory response, a phenotype similar to that of trained immunity, and its etiology involves environmental factors such as β‐glucan exposure. However, whether trained immunity contributes to inflammatory arthritis progression, as well as the reciprocal interactions, remains elusive. The study shows that β‐glucan‐induced experimental trained immunity heighten inflammation and arthritis severity in collagen‐induced arthritis (CIA) rat model. Trained macrophages by β‐glucan, upon adoptive transfer, further intensify symptoms. In arthritis progression, trained macrophages reduce fibroblast‐like synoviocytes’ (FLS) lipid peroxidation, lessening sensitivity to iFSP1‐induced ferroptosis through interleukin‐1 beta (IL‐1β)/N‐acetyltransferase 10 (NAT10)/ferroptosis suppressor protein 1 (FSP1) mRNA ac4C modification. A therapeutic approach targeting trained immunity, combining low‐dose iFSP1 and Remodelin, mitigates arthritis severity and restores ferroptosis sensitivity. Additionally, this interplay between CIA induction and β‐glucan training creates a feedback loop reinforcing trained immune memory, accelerating disease deterioration. The findings highlight trained immunity induced by endogenous or exogenous insult, such as β‐glucan, as an unexplored mechanism of inflammation dysregulation in the pathogenesis of inflammatory arthritis, opening avenues for the therapeutic approaches by targeting trained immunity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immune responses and vaccinations · Immune cells in cancer · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Critical Care Medicine GMU‐GIBH Joint School of Life Sciences The Guangdong‐Hong Kong‐Macao Joint Laboratory for Cell Fate Regulation and Diseases State Key Laboratory of Respiratory Disease Guangzhou Key Laboratory of Prevention and Treatment of Multiple Organ Dysfunction Syndrome the Second Affiliated Hospital Guangzhou Medical University Dongfengxi Road 195 Guangzhou Guangdong 510260 China

Guangzhou National Laboratory Xingdao North Ring Road 9 Guangzhou Guangdong 510006 China

School of Biomedical Engineering Guangzhou Medical University Dongfengxi Road 195 Guangzhou Guangdong 510180 China

Department of Biomedical Sciences Faculty of Health Sciences University of Macau Taipa Macau Macau SAR 999078 China

Funding

National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.1038/s41581-022-00633-510.1038/s41581-022-00633-5 ↗
2. 10.1038/s41590-020-00845-610.1038/s41590-020-00845-6 ↗
3. 10.1126/science.aaf109810.1126/science.aaf1098 ↗
4. 10.1146/annurev-immunol-102119-07385510.1146/annurev-immunol-102119-073855 ↗
5. 10.1016/j.cell.2020.09.05810.1016/j.cell.2020.09.058 ↗
6. 10.1038/s41565-023-01553-610.1038/s41565-023-01553-6 ↗
7. 10.1016/j.celrep.2020.10832510.1016/j.celrep.2020.108325 ↗
8. 10.1038/s41467-019-13636-x10.1038/s41467-019-13636-x ↗
9. 10.1016/j.immuni.2018.09.00810.1016/j.immuni.2018.09.008 ↗
10. 10.1182/blood.202000959410.1182/blood.2020009594 ↗
11. 10.3389/fimmu.2018.0029810.3389/fimmu.2018.00298 ↗
12. 10.1038/s41569-023-00894-y10.1038/s41569-023-00894-y ↗
13. 10.1016/j.jaut.2022.10295610.1016/j.jaut.2022.102956 ↗
14. 10.1056/NEJMra210372610.1056/NEJMra2103726 ↗
15. 10.1046/j.1365-2249.1996.d01-820.x10.1046/j.1365-2249.1996.d01-820.x ↗
16. 10.1084/jem.2015090010.1084/jem.20150900 ↗
17. 10.1016/j.coi.2017.04.01010.1016/j.coi.2017.04.010 ↗
18. 10.1084/jem.2016006110.1084/jem.20160061 ↗
19. 10.1186/s13148-020-00837-110.1186/s13148-020-00837-1 ↗
20. 10.1002/art.4141710.1002/art.41417 ↗
21. 10.1084/jem.2004175810.1084/jem.20041758 ↗
22. 10.1016/j.jaut.2005.06.00210.1016/j.jaut.2005.06.002 ↗
23. 10.1111/j.1348-0421.2006.tb03814.x10.1111/j.1348-0421.2006.tb03814.x ↗
24. 10.1016/j.jbspin.2022.10536410.1016/j.jbspin.2022.105364 ↗
25. 10.1038/s41584-023-01009-010.1038/s41584-023-01009-0 ↗
26. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
27. 10.3389/fimmu.2022.77958510.3389/fimmu.2022.779585 ↗
28. 10.1038/s41467-021-27948-410.1038/s41467-021-27948-4 ↗
29. 10.1186/s12974-021-02231-x10.1186/s12974-021-02231-x ↗
30. 10.1016/j.canlet.2021.12.01110.1016/j.canlet.2021.12.011 ↗
31. 10.1038/nrrheum.2010.410.1038/nrrheum.2010.4 ↗
32. 10.3389/fimmu.2023.126083910.3389/fimmu.2023.1260839 ↗
33. 10.1038/s41580-024-00703-510.1038/s41580-024-00703-5 ↗
34. 10.1002/cac2.1236310.1002/cac2.12363 ↗
35. 10.1038/s41419-023-06245-610.1038/s41419-023-06245-6 ↗
36. 10.1016/j.cell.2022.06.00310.1016/j.cell.2022.06.003 ↗
37. 10.1016/j.cell.2020.04.03910.1016/j.cell.2020.04.039 ↗
38. 10.1038/s41584-020-0413-510.1038/s41584-020-0413-5 ↗
39. 10.3389/fimmu.2022.91666410.3389/fimmu.2022.916664 ↗
40. 10.1016/j.molcel.2023.05.01110.1016/j.molcel.2023.05.011 ↗
41. 10.1038/s41419-023-06182-410.1038/s41419-023-06182-4 ↗
42. 10.1002/mco2.12110.1002/mco2.121 ↗
43. 10.3389/fimmu.2020.63174310.3389/fimmu.2020.631743 ↗
44. 10.1093/rheumatology/keac06910.1093/rheumatology/keac069 ↗
45. 10.1038/s41589-023-01512-110.1038/s41589-023-01512-1 ↗
46. Cavalli G. · Rheumatology · 2015 · 54 · 2134
47. 10.1038/s41420-024-01988-310.1038/s41420-024-01988-3 ↗